首页> 美国卫生研究院文献>British Journal of Clinical Pharmacology >Legal regulations ethical guidelines and recent policies to increase transparency of clinical trials
【2h】

Legal regulations ethical guidelines and recent policies to increase transparency of clinical trials

机译:提高临床试验透明度的法律规定道德准则和最近的政策

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Timely and accurate dissemination of outcomes is essential to accomplish main benefits of scientific research including clinical trials. Clinical trial results can be disseminated in two main ways: by publication in a peer‐reviewed journal and by posting on a publicly available clinical trial register. The credibility of the literature on clinical trials is significantly diminished because a high percentage of trials is not published. While current legal regulations both in the European Union (EU) and the USA impose a duty to submit summary results of clinical trials to a respective register (EU Clinical Trial Register and http://ClinicalTrials.gov, respectively), the compliance with this requirement has been generally inadequate. Trial outcomes can be also made accessible by data sharing. However, in spite of the wide promotion of this idea, the access of investigators to participant‐level datasets remains limited. The main objective of this review is to discuss current legal regulations, international standards, ethical guidelines and recent policies pertaining to dissemination of clinical trial results.
机译:及时,准确地传播结果对于实现科学研究的主要益处至关重要,包括临床试验。临床试验结果可以两种主要方式传播:通过在同行评审期刊中发布,并通过在公开的临床试验登记册上发布。文献对临床试验的可信度明显减少,因为未公布的次数高百分比。虽然欧洲联盟(欧盟)和美国的现行法律规定征税将临床试验的概要结果提交给相应的注册(欧盟临床试验登记册和http://hclinicaltrials.gov),但遵守这一点要求通常不足。可以通过数据共享可以访问试用结果。然而,尽管对这个想法的广泛推广,调查人员对参与者级数据集的访问仍然有限。本综述的主要目标是讨论现有的法律规定,国际标准,道德准则和最近与传播临床试验结果的政策。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号